TransThera Sciences (Nanjing), Inc. (HKG:2617)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
31.40
-0.30 (-0.95%)
Jul 16, 2025, 2:45 PM HKT
45.03%
Market Cap 12.58B
Revenue (ttm) n/a
Net Income (ttm) -292.23M
Shares Out 396.90M
EPS (ttm) -0.77
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 182,000
Average Volume 1,312,924
Open 31.95
Previous Close 31.70
Day's Range 30.75 - 32.95
52-Week Range 20.20 - 35.00
Beta n/a
RSI 68.49
Earnings Date n/a

About HKG:2617

TransThera Sciences (Nanjing), Inc., clinical stage biopharmaceutical company, discovers, develops, and commercializes small molecule therapies for oncology, inflammatory, and cardiometabolic diseases. The company provides Tinengotinib (TT-00420), a MTK inhibitor for the treatment of drug-resistant, relapsed, or refractory cancers. It also develops a pipeline of clinical stage product candidates and a preclinical stage product candidate. TransThera Sciences (Nanjing), Inc. was formerly known as Nanjing TransThera Biosciences Co. Ltd. and change... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Country China
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2617
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.